Imaging techniques used in the diagnosis, staging, and followup of patients with myeloma

Acta Radiologica

Volumn 46, Issue 7, 2005, Pages 716-724

  Mulligan, M E ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Computed tomography; Imaging; Magnetic resonance; Multiple; Myeloma; Plasmacytoma

Indexed keywords

CELLS; DIAGNOSIS; MAGNETIC RESONANCE IMAGING; PATIENT TREATMENT; RADIOLOGY;

MULTIPLE; MYELOMA; PLASMACYTOMA;

MEDICAL IMAGING;

ADULT; AGED; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMACYTOMA; POSITRON EMISSION TOMOGRAPHY; REVIEW;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHIES, BENIGN; MULTIPLE MYELOMA; NEOPLASM STAGING; PLASMACYTOMA; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33644812871     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1080/02841850500215360     Document Type: Review

References (32)

1. Alexandrakis M, Kyriakou D, Passam F, Malliaraki N, Christophoridou A, Karkavitsas N. Correlation between the uptake of Tc-99m-sestaMIBI and prognostic factors in patients with multiple myeloma. Clin Lab Haematol 2002;24:155-9.
2. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994;330:484-9.
3. Angtuaco E, Fassas A, Walker R, Sethi R, Barlogie B. Multiple myeloma: clinical review and diagnostic imaging. Radiology 2004;231:11-23.
4. Baur A, Stabler A, Nagel D, Lamerz R, Bartl R, Hiller E, et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer 2002;95:1334-45.
5. Buhmann S, Baur-Melnyk A, Wieser A, Reiser M. Diagnostics of multiple myeloma using a 16-row-MSCT: low-dose whole body protocol. European Congress of Radiology. March 2005.
6. Chen-Kiang S. Plasma cells and multiple myeloma. Immunol Rev 2003;194:5-7.
7. Durie B, Kyle R, Belch A, Bensinger W, Blade J, Boccadoro M, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003; 4:379-98.
8. Durie B, Waxman A, D'Agnolo A, Williams C. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med 2002;43:1457-63.
9. Durie B, Salmon S. A clinical staging system for multiple myeloma. Cancer 1975;36:842-54.
10. Garcia-Sanz R, Gonzalez-Fraile M, Mateo G, Hernandez J, Lopez-Berges M, de las Heras N, et al. Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. Tnt J Cancer 2004;112:884-9.
11. Hargaden G, O'Connell M, Kavanagh E, Powell T, Ward R, Eustace S. Current concepts in whole-body imaging using turbo short tau inversion recovery MR imaging. Am J Roentgenol 2003; 180:247-52.
12. Hartman R, Sundaram M, Okuno S, Sim F. Effect of granulocyte-stimulating factors on marrow of adult patients with musculoskeletal malignancies: incidence and MRI findings. Am J Roentgenol 2004; 183:645-53.
13. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.
14. Jadvar H, Conti P. Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol 2002;31:690-4.
15. Kyle R, Gertz M, Witzig T, Lust J, Lacy M, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33.
16. Kyle R, Rajkumar S. Monoclonal gammopathies of undetermined significance: a review. Immunol Rev 2003:194:112-39.
17. Lacy M, Gertz M, Hanson C, Inwards D, Kyle R. Multiple myeloma associated with diffuse osteosclerotic bone lesions: a clinical entity distinct from osteosclerotic myeloma (POEMS syndrome). Am J Hematol 1997; 56:288-93.
18. Lecouvet F, Dechambre S, Malghem J, Ferrant A, Vande Berg B, Maldague B. Bone marrow transplantation in patients with multiple myeloma: prognostic significance of MR imaging. Am J Roentgenol 2001; 176:91-6.
19. Lecouvet F, Malghem J, Michaux L, Maldague B, Ferrant A, Michaux J, et al. Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey. Br J Haematol 1999;106:35-9.
20. Mahnken A, Wildberger J, Gehbauer G, SchmitzRode T, Blaum T, Fabry U, et al. Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. Am J Roentgenol 2002; 178:1429-36.
21. Mendenhall W, Mendenhall C, Mendenhall N. Solitary plasmacytoma of bone and soft tissues. Am J Otolaryngol 2003;24:395-9.
22. Mileshkin L, Blum R, Seymour J, Patrikeos A, Hicks R, Prince H. A comparison of FDG PET and Tc-99m sestamibi in assessing patients with multiple myeloma. Eur J Haematol 2004;72:32-7.
23. Miralles G, O'Fallon J, Talley N. Plasma-cell dyscrasia with polyneuropathy. The spectrum of POEMS syndrome. N Engl J Med 1992;327:1919-23.
24. Moulopoulos L, Dimopoulos M, Weber D, Fuller L, Libshitz H, Alexanian R. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol 1993;11:1311-15.
25. Mulleman D, Gaxatte C, Guillerm G, Leroy X, Cotton A, Duquesnoy B, et al. Multiple myeloma presenting with widespread osteosclerotic lesions. Joint Bone Spine 2004;71:79-83.
26. Mulligan M. Myeloma and lymphoma. Semin Musculoskelet Radiol 2000;4:127-35.
27. Schirrmeister H, Buck A, Bergmann L, Reske S, Bommer M. Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm 2003;18:841-5.
28. Sirohi B, Powles R. Multiple myeloma. Lancet 2004;363:875-7.
29. Sohn S, Ahn B, Lee S, Kim D, Chun K, Kim J, et al. Bone marrow immunoscintigraphy using technetium99m anti-granulocyte antibody in multiple myeloma. Eur J Nucl Med Mol Imaging 2002;29:591-6.
30. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole D, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995;86: 4250-56.
31. Tsang R, Gospodarowicz M, Pintilie M, Bezjak A, Wells W, Hodgson D, et al. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys 2001;50: 113-20.
32. Weber D, Dimopoulos M, Moulopoulos L, Delasalle K, Smith T, Alexanian R. Prognostic features of asymptomatic multiple myeloma. Br J Haematol 1997; 97:810-14.